Article
Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients.
Drug design, development and therapy - 1 Jan 2021
Hasanah Yesi Ihdina Fityatal, Harahap Yahdiana, Purwanto Denni Joko
Abstract excerpt
BACKGROUND: Cyclophosphamide (CP) is an anticancer alkylating group (nitrogen mustard) and a prodrug that will be metabolized to form its active metabolite, 4-hydroxycyclophosphamide (4-OHCP). The various enzymes involved in its bioactivation can cause a wide range of CP expression and activity among patients and ultimately affect the metabolism, efficacy and toxicity of this drug. The effectiveness of CP therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.